TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26643240

Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium, 2.5 mg, 1/d for 11 d
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low molecular weight heparin, 4100 U, 1/12 h for 11 d
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low molecular weight heparin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 36
Study: 24738240

Group type: EXPERIMENTAL
Intervention: cycloferon + lamivudine for 48 weeks
Number of subjects: 647

Group type: COMPARATOR
Intervention: lamivudine + placebo for 48 weeks
Number of subjects: 647
Study: 21372069

Group type: EXPERIMENTAL
Intervention: Family-based behavioral intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 58
Study: 19644973

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 204

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 204
Study: 17653532

Group type: EXPERIMENTAL
Intervention: Mirtazapine (7.5 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15853576

Group type: EXPERIMENTAL
Intervention: Natalizumab (300 mg intravenous infusion, administered monthly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11881837

Group type: EXPERIMENTAL
Intervention: 400 mg naftidrofuryl/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600 mg naftidrofuryl/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9777836

Group type: EXPERIMENTAL
Intervention: Standard diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (female controls)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Patients on exclusion diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Standard diet after lactulose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 12
Study: 7892744

Group type: EXPERIMENTAL
Intervention: Radiotherapy with curative intent for T2 stage patients
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Radiotherapy with curative intent for T3/T4 stage patients
Number of subjects: 158

Group type: COMPARATOR
Intervention: Subclinical malignancy treated with radiotherapy
Number of subjects: 158
Study: 3115770

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 29425387

Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 70

Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 70
Study: 27514859

Group type: EXPERIMENTAL
Intervention: Tailored Web-based health feedback
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Tailored Web-based health feedback + optional telephone coaching
Number of subjects: 981

Group type: COMPARATOR
Intervention: No health feedback or telephone coaching (Control group A)
Number of subjects: 981
Study: 26224765

Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg
Number of subjects: 350

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 350
Study: 23507346

Group type: EXPERIMENTAL
Intervention: Pelvic fitness program (6-week duration, twice a week)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Education-only group (1 educational session and a booklet)
Number of subjects: 43
Study: 21042116

Group type: EXPERIMENTAL
Intervention: Avotermin 200 ng/100 μl/linear centimeter, administered once or twice
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Avotermin 50 ng/100 μl/linear centimeter, administered twice
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (no injection)
Number of subjects: 71
Study: 18604623

Group type: EXPERIMENTAL
Intervention: Various definitions for excess body fat (age-independent cut points)
Number of subjects: 6205

Group type: EXPERIMENTAL
Intervention: Various definitions for excess body fat (age-dependent cut points)
Number of subjects: 6205

Group type: COMPARATOR
Intervention: Various definitions for excess body fat
Number of subjects: 6205
Study: 16979687

Group type: EXPERIMENTAL
Intervention: Inverted head position (15 observers)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Erect position (15 observers)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Prism goggles (15 observers)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bending head forward with goggles (15 observers)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Hollow goggles while lying on belly (15 observers)
Number of subjects: 90
Study: 14609611

Group type: EXPERIMENTAL
Intervention: Physiologic testosterone therapy
Number of subjects: 0
Study: 12467086

Group type: EXPERIMENTAL
Intervention: Categorization task without exposure to training sequence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classification and recognition performance tested immediately or after a week delay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cued-recall task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Categorization task
Number of subjects: 0
Study: 9606843

Group type: EXPERIMENTAL
Intervention: Blockade of fibrinolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High level of inhibitors and platelets hypoaggregation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggravation of patient's state post-operation
Number of subjects: 0
Study: 7949553

Group type: EXPERIMENTAL
Intervention: Single-photon emission computed tomography (SPECT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 14

Group type: COMPARATOR
Intervention: Mild human immunodeficiency virus (HIV) encephalopathy patients
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: SPECT
Number of subjects: 14
Study: 2453683

Group type: EXPERIMENTAL
Intervention: Enoxacin 200 mg, administered orally the night before the operation, 2 to 4 hours preoperatively, and every 12 hours postoperatively for 36 hours.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo, administered in the same manner as enoxacin.
Number of subjects: 40
Study: 30957112

Group type: EXPERIMENTAL
Intervention: Curvature-analysis method
Number of subjects: 27

Group type: COMPARATOR
Intervention: Line-drawing method
Number of subjects: 27

Group type: COMPARATOR
Intervention: Powder-coating method
Number of subjects: 27
Study: 28938446

Group type: EXPERIMENTAL
Intervention: Vitamin D3 20,000 IU/wk for 12 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 25153574

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: T1D patients
Number of subjects: 28
Study: 23453347

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214

Group type: COMPARATOR
Intervention: Lithium vs Placebo
Number of subjects: 214
Study: 21447515

Group type: EXPERIMENTAL
Intervention: Ortho All‐Flex Diaphragm and lubricant gel (Replens) with condoms
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Condoms alone
Number of subjects: 2016
Study: 18092150

Group type: EXPERIMENTAL
Intervention: Terlipressin (TP) administered as intravenous bolus doses of 20 microg/kg every 6 h for a maximum of 96 h
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Terlipressin (TP)
Number of subjects: 58
Study: 16580383

Group type: EXPERIMENTAL
Intervention: 60 mg/day isoflavones
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 12743669

Group type: COMPARATOR
Intervention: Fluticasone 500 microg (FP), 1 puff b.i.d.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fluticasone 250 microg plus salmeterol 50 microg (FP+SM), 1 puff b.i.d.
Number of subjects: 15
Study: 10683715

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium salt 50 mg in sachet (Voltfast)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium salt 50 mg in tablet (Cataflam)
Number of subjects: 24
Study: 9086683

Group type: EXPERIMENTAL
Intervention: Body Sensations Interpretation Questionnaire (BSIQ) administered to panic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Body Sensations Interpretation Questionnaire (BSIQ) administered to controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief version of the BSIQ
Number of subjects: 0
Study: 8229120

Group type: EXPERIMENTAL
Intervention: IL-3 at doses > or = 2.5 micrograms/kg/d
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: IL-3 at doses 7.5 and 10 micrograms/kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: IL-3 at doses > or = 2.5 micrograms/kg
Number of subjects: 28

Group type: COMPARATOR
Intervention: IL-3
Number of subjects: 28
Study: 31321713

Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF)
Number of subjects: 2153

Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC)
Number of subjects: 2153

Group type: EXPERIMENTAL
Intervention: Vilanterol (VI)
Number of subjects: 2153

Group type: COMPARATOR
Intervention: Combination of FF/UMEC/VI
Number of subjects: 2153
Study: 30691752

Group type: EXPERIMENTAL
Intervention: Early-mobilization group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Late-mobilization group
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined joint mobilization and calf stretching
Number of subjects: 10
Study: 28395185

Group type: EXPERIMENTAL
Intervention: Prosocial behavior towards specific others
Number of subjects: 159

Group type: COMPARATOR
Intervention: Prosocial behavior directed towards the world in general
Number of subjects: 159

Group type: COMPARATOR
Intervention: Self‐focused kindness
Number of subjects: 159

Group type: COMPARATOR
Intervention: Neutral control task
Number of subjects: 159
Study: 25236397

Group type: EXPERIMENTAL
Intervention: Smaller pouch size group (10-20 ml)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Larger pouch size group (25-35 ml)
Number of subjects: 76
Study: 21737162

Group type: COMPARATOR
Intervention: Moderate wine intake (up to 0.5L/day)
Number of subjects: 11248

Group type: COMPARATOR
Intervention: Wine consumption up to 0.5L/day
Number of subjects: 11248

Group type: COMPARATOR
Intervention: >0.5L/day wine consumption
Number of subjects: 11248

Group type: EXPERIMENTAL
Intervention: Non-drinkers
Number of subjects: 11248
Study: 21669298

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine therapy for newly diagnosed extensive cGVHD
Number of subjects: 63
Study: 18955740

Group type: EXPERIMENTAL
Intervention: Large jar
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Small jar
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy controls (large jar)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy controls (small jar)
Number of subjects: 14
Study: 15699772

Group type: EXPERIMENTAL
Intervention: RhuEPO 100 U/kg three times per week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-EPO group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RhuEPO group
Number of subjects: 40
Study: 12850361

Group type: EXPERIMENTAL
Intervention: RSV PFP-2 vaccine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 10100251

Group type: EXPERIMENTAL
Intervention: 4 mm capsulorhexis
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 6 mm capsulorhexis
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both groups (4 mm and 6 mm capsulorhexis)
Number of subjects: 51
Study: 8724922

Group type: EXPERIMENTAL
Intervention: 6% glucose/sucrose solution at the rate of 0.6 g.kg‐1 (Body Weight).hr.‐1
Number of subjects: 7

Group type: COMPARATOR
Intervention: Artificially flavored placebo
Number of subjects: 7
Study: 1853142

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (no immunotherapy)
Number of subjects: 226
Study: 6357106

Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxycholecalciferol (10 ng/kg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Calciferol (670 ng/kg/day)
Number of subjects: 16
Study: 31725877

Group type: EXPERIMENTAL
Intervention: Infertility consultations for females
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Infertility consultations for males
Number of subjects: 100000
Study: 28284205

Group type: EXPERIMENTAL
Intervention: 3D models of tetralogy of Fallot (n=18)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 2D drawings of tetralogy of Fallot (n=17)
Number of subjects: 35
Study: 29231292

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Manual acupuncture (MA)
Number of subjects: 68
Study: 24176063

Group type: EXPERIMENTAL
Intervention: SYNTAX score tertiles for MVD (<5, ≥5 but <10, ≥10)
Number of subjects: 2627

Group type: EXPERIMENTAL
Intervention: SYNTAX score tertiles for SVD (<5, ≥5 but <10, ≥10)
Number of subjects: 2627

Group type: EXPERIMENTAL
Intervention: SYNTAX score for MVD
Number of subjects: 2627

Group type: EXPERIMENTAL
Intervention: SYNTAX score for SVD
Number of subjects: 2627
Study: 22864880

Group type: EXPERIMENTAL
Intervention: Endoluminal locoregional resection (ELRR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laparoscopic total mesorectal excision (TME)
Number of subjects: 100
Study: 19288005

Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: COPPEBVCAD
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BEACOPP
Number of subjects: 38
Study: 17347903

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy with 5-fluorouracil plus polysaccharide K
Number of subjects: 202

Group type: COMPARATOR
Intervention: Chemotherapy with 5-fluorouracil alone
Number of subjects: 202
Study: 14506079

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (bicycle training, up to 45 min at 80% peak heart rate, 3-4 days/week)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (flexibility activity)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Age-related decline
Number of subjects: 78
Study: 11486115

Group type: EXPERIMENTAL
Intervention: Hypothermia to 32±1 degrees C for 12 to 72 hours
Number of subjects: 10

Group type: COMPARATOR
Intervention: Concurrent controls (9 patients)
Number of subjects: 10
Study: 9738164

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 2986
Study: 2897987

Group type: EXPERIMENTAL
Intervention: Theophylline treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 16
Study: 31948302

Group type: EXPERIMENTAL
Intervention: External/internal Tiaoqiheying decoction
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: External Tiaoqiheying decoction
Number of subjects: 102
Study: 31738759

Group type: EXPERIMENTAL
Intervention: Guppy fish
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Pyriproxyfen (PPF)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both interventions (Guppy fish and PPF)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Health education through health volunteers
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Interpersonal communication through health volunteers
Number of subjects: 103
Study: 27908900

Group type: EXPERIMENTAL
Intervention: Democratic therapeutic community (DTC) treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Crisis planning plus treatment as usual (TAU)
Number of subjects: 70
Study: 25988762

Group type: EXPERIMENTAL
Intervention: Chia seed oil (7 kcal kg‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water alone (control)
Number of subjects: 24
Study: 23160364

Group type: EXPERIMENTAL
Intervention: Duloxetine (60mg/d)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Escitalopram (10mg/d)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No antidepressant therapy (control group)
Number of subjects: 75
Study: 21770848

Group type: EXPERIMENTAL
Intervention: Guided internet-delivered cognitive behavior therapy (CBT) for GAD, 8-week treatment
Number of subjects: 89

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 89
Study: 19157347

Group type: EXPERIMENTAL
Intervention: Familiar animal sound (one of two sounds)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Degraded versions of the animal sounds mixed with white noise
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Distractor task
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Degraded auditory stimulus test
Number of subjects: 93
Study: 16990238

Group type: EXPERIMENTAL
Intervention: Checkpoints Program
Number of subjects: 3743

Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 3743
Study: 12820485

Group type: COMPARATOR
Intervention: CPT-11 alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPT-11 plus MLT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPT-11 at 50% dose reduction
Number of subjects: 30
Study: 11261630

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard closure (no glue)
Number of subjects: 27
Study: 8651473

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 1% nasal spray QID + astemizole
Number of subjects: 365

Group type: COMPARATOR
Intervention: Astemizole alone
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo nasal spray + astemizole
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Combined therapy (nedocromil sodium + astemizole)
Number of subjects: 365
Study: 1347103

Group type: EXPERIMENTAL
Intervention: 20 mg lovastatin daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg lovastatin daily
Number of subjects: 12
Study: 6734045

Group type: EXPERIMENTAL
Intervention: Nifedipine (18.5 +/- 4 mg every 8 hr)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 20
Study: 31903334

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) only, 50 mg/kg administered intravenously before surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tranexamic acid combined with vitamin C (TXC), 50 mg/kg TA and 2 g vitamin C with 100 mL 0.9% saline administered before surgery and daily infusions post-operation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (TA and TXC)
Number of subjects: 120
Study: 28922910

Group type: EXPERIMENTAL
Intervention: Vitamin A combined with vitamin B combined with recombinant human erythropoietin (group C)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Vitamin A combined with recombinant human erythropoietin (group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Vitamin B combined with recombinant human erythropoietin (group B)
Number of subjects: 150
Study: 27815591

Group type: EXPERIMENTAL
Intervention: Vitamin E-blended HXLPE
Number of subjects: 100

Group type: COMPARATOR
Intervention: UHMWPE
Number of subjects: 100
Study: 25889308

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID (Period 1)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo BID (Period 2)
Number of subjects: 148
Study: 24086333

Group type: EXPERIMENTAL
Intervention: Daily oral Tenofovir/Emtricitabine (TDF/FTC‐Truvada)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intermittent oral Tenofovir/Emtricitabine (TDF/FTC)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Post‐coital dosing of Tenofovir/Emtricitabine (TDF/FTC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 20864577

Group type: EXPERIMENTAL
Intervention: Influenza-primed autologous T-cell product
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nonspecifically primed autologous T-cell product
Number of subjects: 21
Study: 19462826

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Number of subjects: 284

Group type: COMPARATOR
Intervention: Dutasteride 2.5 mg
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 18046292

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 50 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 15521923

Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin
Number of subjects: 0
Study: 12031997

Group type: EXPERIMENTAL
Intervention: PAC insertion before induction of anesthesia
Number of subjects: 200

Group type: COMPARATOR
Intervention: PAC insertion after induction of anesthesia
Number of subjects: 200
Study: 9732632

Group type: EXPERIMENTAL
Intervention: Air bubble technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Z-track technique
Number of subjects: 0
Study: 8071268

Group type: EXPERIMENTAL
Intervention: Bright light treatment
Number of subjects: 30
Study: 3123091

Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA (50 mg over 2 hr)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intrapulmonary rt-PA (50 mg over 2 hr)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intrapulmonary rt-PA (100 mg over 5 hr)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA (100 mg over 5 hr)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Both groups (Intravenous and Intrapulmonary rt-PA)
Number of subjects: 34
Study: 31801814

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Lactobacillus reuteri
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 29899061

Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg) for four weeks before quitting
Number of subjects: 1792

Group type: COMPARATOR
Intervention: Control group (standard smoking cessation pharmacotherapy and behavioral support)
Number of subjects: 1792
Study: 27583380

Group type: EXPERIMENTAL
Intervention: Late surfactant plus inhaled nitric oxide
Number of subjects: 511

Group type: COMPARATOR
Intervention: Inhaled nitric oxide alone
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Tracheotomy
Number of subjects: 511
Study: 25246645

Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 41

Group type: COMPARATOR
Intervention: IVMP
Number of subjects: 41
Study: 24490521

Group type: EXPERIMENTAL
Intervention: Carboxymethl starch sodium solution (3 mL/times for 1-3 years old, 5 mL/times for 4-7 years old, 7 mL/times for 8-14 years old, 3 times/day) + inhaled budesonide
Number of subjects: 96

Group type: COMPARATOR
Intervention: Inhaled budesonide (500 microg/times for 1-5 years old, 1 mg/times and 2 times/day for 6-14 years old)
Number of subjects: 96